Surmodics, Inc. provided earnings guidance for the year 2024. For the year, the company expects total revenue to range from $116 million to $121 million, representing a decrease of (13)% to (9)% compared to fiscal 2023. The company expects fiscal 2024 GAAP diluted loss per share to range from $1.55 to $1.20.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.14 USD | -0.13% | +3.07% | -28.01% |
Feb. 06 | Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating | MT |
Feb. 01 | Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.01% | 373M | |
-2.89% | 187B | |
-2.23% | 106B | |
-4.60% | 66.9B | |
+0.69% | 49.45B | |
+16.64% | 48B | |
+4.06% | 40.84B | |
+3.45% | 26.48B | |
+1.20% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- SRDX Stock
- News Surmodics, Inc.
- Surmodics, Inc. Provides Earnings Guidance for the Year 2024